Clinical trials: CD20 Positive
B-cell Non Hodgkin's Lymphoma
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
Randomised, double-blind, parallel group study to compare PK and PD profiles between HLX01 and rituximab (MabThera®) in patients with CD20+ B-cell Lymphoma.
- Trial name
- NCT02584920
- Testing
- HLX01, Rituximab
- Volunteers
- 87 people
- Sponsor
- Shanghai Henlius Biotech
Lymphoma, Large B-Cell, Diffuse
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously…
- Trial name
- NCT01649856
- Testing
- CHOP, rituximab [MabThera/Rituxan]
- Where
- 186 sites in Algeria, Argentina and 25 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Lymphoproliferative Disorder
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, prednisone, and methylprednisolone use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00066469
- Testing
- rituximab, cyclophosphamide, methylprednisolone
- Where
- 78 sites in United States, Australia and 2 more
- Volunteers
- 55 people
- Sponsor
- Children's Oncology Group
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
MB-CART20.1 Lymphoma
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
- Trial name
- NCT03664635
- Testing
- MB-CART20.1
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Miltenyi Biomedicine GmbH
B-Cell Lymphoma
A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients
Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma
- Trial name
- NCT02945215
- Testing
- IBI301, Rituximab
- Where
- 12 sites in China
- Volunteers
- 181 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma
Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma
This partially randomized phase I trial studies the side effects and best dose of ipilimumab when given together with rituximab in treating patients with B-cell lymphoma that has returned or has not responded to treatment.
- Conditions
- CD20 Positive, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT01729806
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Rituximab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis B, Lymphoma
Tenofovir to Prevent HBV Reactivation
The purpose of the study is to determine how effective preemptive tenofovir therapy is in preventing the re-activation of Hepatitis B infection, in patients who are receiving rituximab-based chemotherapy for Non-Hodgkin's…
- Conditions
- Hepatitis B, Lymphoma, Non-Hodgkin
- Trial name
- NCT02186574
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Canada
- Volunteers
- 184 people
- Sponsor
- University Health Network, Toronto
CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders.
- Conditions
- CD20-Positive Lymphoid Malignancies, Chronic Lymphoid Leukemia, Hematological Malignancies, Non-Hodgkin's Lymphoma
- Trial name
- NCT00788684
- Testing
- rituximab, ABT-263
- Where
- 6 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- AbbVie
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma
Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy with or without peripheral stem cell transplantation in treating patients who have recurrent or refractory lymphoma.
- Conditions
- AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma
- Trial name
- NCT00036855
- Testing
- rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Resolved Hepatitis B, CD20 Positive B-cell Lymphoma
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody)
This phase 2 trial aims to evaluate the efficacy of entecavir prophylacxis for hepatitis B virus (HBV) reactivation that continues until 6 months after completing CD20 monoclonal antibody therapy in patients with CD20-positive…
- Trial name
- REHEB (NCT05453435)
- Testing
- Entecavir
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Sun Yat-sen University
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278421
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 78 sites in Germany, Israel and 1 more
- Volunteers
- 592 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
B-NHL
An Evaluation of LY007 Cell Injection for r/r B-NHL
An evaluation of LY007 cell injection for recurrent/refractory CD20 was positive Tolerability, safety, and efficacy of B-cell non-Hodgkin lymphoma in open, single-arm Phsea I Clinical research
- Trial name
- r/r B-NHL (NCT06364852)
- Testing
- LY007
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Ruijin Hospital
PTLD, Posttransplant Lymphoproliferative Disorder
Risk Stratified Sequential Treatment for CD20-positive PTLD
This phase-II trial will investigate the efficacy, safety and the tolerability of a sequential therapy consisting of 4 courses of single agent rituximab followed by 4 courses of R-CHOP chemotherapy in patients with CD20+…
- Trial name
- PTLD-1/3 (NCT00590447)
- Testing
- rituximab monotherapy, sequential R-CHOP
- Where
- 7 sites in Australia, Belgium and 5 more
- Volunteers
- 152 people
- Sponsor
- Charite University, Berlin, Germany
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
This phase Ib trial studies the effects of venetoclax in combination with dasatinib, prednisone, rituximab and blinatumomab in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) that is…
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Trial name
- NCT04872790
- Testing
- Dasatinib, Methotrexate, Prednisone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm
Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
This phase II trial studies the side effects and best dose of bortezomib when given with chemotherapy and to see how well they work in treating participants with lymphoid malignancies undergoing stem cell transplant.
- Conditions
- CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
- Trial name
- NCT00439556
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bortezomib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
DLBCL
A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of MabThera® and TL011, in combination with CHOP in…
- Trial name
- NCT01205737
- Testing
- TL011, Rituximab
- Where
- 41 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 186 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL) patients.
- Trial name
- NCT00742144
- Testing
- ofatumumab
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Follicular Lymphoma
Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
The primary objective of the current study is to demonstrate the equivalent efficacy of rituximab (DRL_RI) and MabThera® in subjects with Low Tumor Burden Follicular Lymphoma (LTB-FL).
- Trial name
- FLINTER (NCT03976102)
- Testing
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Where
- 4 sites in United States
- Volunteers
- 317 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies
This study will evaluate the safety and efficacy of 1A46 in adult patients with advanced CD20 and/or CD19 positive B-cell non-Hodgkin's lymphoma (NHL) or acute lymphoblastic leukemia (ALL).
- Trial name
- NCT05348889
- Testing
- 1A46 Injection
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Chimagen Biosciences, Ltd
Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
This phase I/II trial studies the side effects and best dose of nivolumab and how well it works when giving together with combination chemotherapy in treating participants with diffuse large B-cell lymphoma.
- Conditions
- Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable
- Trial name
- NCT03704714
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University